Johnson & Johnson, founded in 1886, makes and sells medical devices, pharmaceuticals, and consumer health products. Headquartered in New Brunswick, N.J., the company operates over 250 subsidiary ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $89.2 billion to $90 billion. This story was generated by Automated Insights ( ...

In the latest trading session, Johnson & Johnson (JNJ) closed at $147.77, marking a +1.93% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.21%. Elsewhere ...

Johnson & Johnson has won Food and Drug Administration ... patients with generalized myasthenia gravis. The New Brunswick, N.J., pharmaceutical giant on Thursday said nipocalimab, if approved ...

Could Johnson & Johnson’s talcum powder litigation, now in its second decade, come to an end in 2025? Or are more legal and legislative battles on the horizon? Johnson & Johnson enters the New ...

Drugmaker Johnson & Johnson must pay $572m (£468m ... The State failed to present evidence that the company's products or actions caused a public nuisance in Oklahoma," it said.

Johnson & Johnson says the safety of its talcum ... in damages to 22 women who alleged that its talc products caused them to develop ovarian cancer. A jury in the US state of Missouri initially ...